Supernus to Host Fourth Quarter and Full Year 2013 Earnings Conference Call

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company expects to report fourth quarter and full year 2013 financial results after the market closes Wednesday, March 12, 2014. CEO, Jack Khattar, and CFO, Greg Patrick, will be hosting a conference call on Thursday, March 13, 2014 at 9:00 AM Eastern Time, to discuss 2013 financial results and to provide a business update.

A live webcast will be available at www.supernus.com. Following the live call, a replay will be available on the Company's website under ’Investor Info’. The webcast will be archived on the Company's website for 30 business days following the live call.

Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.

    
      
        
        
        
           
        
        
           
        
        
        
      
      
        
          Conference dial-in:
        
        
        
        
        
        
          877-288-1043
        
      
      
        
          International dial-in:
        
        
        
        
        
        
          970-315-0267
        
      
      
        
          Conference ID:
        
        
        
        
        
        
          54977145
        
      
      
        
          

Conference Call Name:

Supernus Pharmaceuticals 4Q 2013 Earnings Conference Call

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR™ (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

Supernus Pharmaceuticals, Inc.Jack A. Khattar, 301-838-2591President and CEOorGregory S. Patrick, 301-838-2591Vice President and CFOorInvestor Contact:Cockrell Group, [e-mail]